X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADVM-022 (ixoberogene soroparvovec) is a gene therapy product candidate, which utilizes a vector capsid, AAV.7m8, carrying aflibercept coding sequence. It is being evaluated in phase 2 clinical trials for the treatment of neovascular or wet age-related macular degeneration.
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
ADVM-022 (Ixoberogene soroparvovec) is utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette, which is investigated for the treatment of wet AMD.
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Under the agreement, Adverum grants Ray Therapeutics a worldwide, non-exclusive license of AAV.7m8 together with its RTx-015 asset, for the prevention, treatment, diagnosis or amelioration of any ocular disorder utilizing Ray’s optogenetics approach.
Lead Product(s): RTx-015,AAV.7m8
Therapeutic Area: Genetic Disease Product Name: RTx-015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ray Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 12, 2023
Details:
ADVM-022, (ixoberogene soroparvovec (Ixo-vec), is clinical-stage gene therapy product candidate being developed for treatment of wet AMD, utilizes proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under control of proprietary expression cassette.
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
ADVM-022 (Ixoberogene Soroparvovec) utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette.
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
OPTIC trial participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous therapeutic aflibercept protein expression levels through three years following a single, in-office intravitreal injection of ADVM-022 (ixoberogene soroparvovec).
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
ADVM-022 (ixoberogene soroparvovec),utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette for the treatment of wet AMD.
Lead Product(s): Ixoberogene Soroparvovec
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product, is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.
Lead Product(s): AAV.7m8-Aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 (AAV.7m8-Aflibercept) in OPTIC study subjects with wet age-related macular degeneration (wet AMD).
Lead Product(s): AAV.7m8-Aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept), utilizes a propriety vector capsid, AAV.7m8 for wet AMD shows therapeutic levels of aflibercept out to three years.
Lead Product(s): AAV.7m8-aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
